|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ABO/Rh for RhIG candidacy
MessageLabeling must be performed at the patient’s bedside, immediately following specimen collection, by the person who collected the specimen.
Specimens will be rejected if there is evidence that the labeling did not take place at the bedside (i.e. double labeling).
Specimens will be rejected if there is evidence that the labeling did not take place at the bedside (i.e. double labeling).
Test Code
ABORH
Alias/See Also
ABO/Rh RhIG Candidate, ABORH
Includes
ABO Group, Rh Type
If the ABO/Rh typing reveals the patient is Rh-negative or weak D positive, an antibody screen will be performed . Antibody identification procedures will be followed if the antibody screen is positive. RhIG is NOT indicated if the patient has a current or historical record of anti-D.
If the ABO/Rh typing reveals the patient is Rh-negative or weak D positive, an antibody screen will be performed . Antibody identification procedures will be followed if the antibody screen is positive. RhIG is NOT indicated if the patient has a current or historical record of anti-D.
Preferred Specimen
4 mL whole blood (2 mL minimum)
Instructions
Must be legibly labeled with the following:
A. Patient’s complete name
B. Patient’s medical record number
C. Date and time of collection
D. Identification of person collecting the specimen
Specimens may be labeled with an LIS label, hospital generated label, or handwritten label. The patient name may be truncated due to space limitations on the label; these are acceptable.
Transport Container
EDTA (lavender/purple) preferred.
Specimen Stability
Room temperature: 24 hours
Refrigerated: <10 days
Frozen: Unacceptable
Refrigerated: <10 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Any collection container containing serum-separator (SST)
Improper, incorrect or incomplete labeling
Improper, incorrect or incomplete labeling
Report Available
Same day
Limitations
Identification and quantification of fetal bleed must be performed if the patient is >20 weeks gestation.
A. If the blood type of the fetus is not known, a Kleihauer-Betke test must be performed.
B. If the blood type of the fetus is known (unlikely) and both mom and baby meet acceptability specifications, a fetal cell screen may be performed to determine if a fetal bleed has occurred before performing Kleihauer-Betke testing.
RhIG should be administered to any patient who is Rh-negative and has no current or historical record of anti-D.
A. 1 vial of RhIG is given to patients who are < 20 weeks gestation.
B. The amount of RhIG given to patients who are > 20 weeks gestation will be determined by fetal bleed screen and/or Kleihauer-Betke test results. One vial of RhIG may be given prior to completion of testing.
Clinical Significance
This test is generally only ordered on pregnant females who have experienced a possible sensitization of fetal blood.
